TYR and melanoma: However, it should be noted that no severe adverse effects in normal tissues or organs have been reported in the clinical trials of cancer vaccines specific to the MAGE-1, MAGE-3, Melan-A, gp100, tyrosinase, and NY-ESO-1 in melanoma patients, although these molecules are expressed in the normal testis, retina, and/or melanocytes at both the mRNA and protein levels (Hu et al, 1996; Marchand et al, 1998; Rodolfo and Colombo, 1999; Thurner et al, 1999; Mackensen et al, 2000; Jager et al, 2001).